• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Wockhardt receives US FDA approval for Olopatadine HCI

financialexpressJuly 04, 2017

Tag: WOCKHARDT , FDA

Wockhardt has received final approval from US FDA for its ANDA for 0.1 per cent ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1 per cent ophthalmic solution is a generic version of Patanol, marketed at a US by Alcon, a subsidiary of Novartis

The product will be manufactured at US FDA approved contract manufacturing organisation based in Montreal, Canada.

Previous:Convergence of Blockchain with Emerging Technologies Set to Disrupt the Healthcare Industry by 2025

Next:Domino Printech India to launch Ax-Series

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Wockhardt receives US FDA approval for Olopatadine HCI | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Nabumetone (FDA)

Nabumetone (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Ribavirin (FDA)

Ribavirin (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Irinotecan (FDA)

Irinotecan (FDA)
Tobramycin base( FDA)

Tobramycin base( FDA)
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
Deoxycyline (FDA)

Deoxycyline (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service